New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2013
11:55 EDTODP, TMO, PPHM, FE, RIGLHigh option volume stocks: FE TMO RIGL PPHM ODP
News For FE;TMO;RIGL;PPHM;ODP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 29, 2015
14:22 EDTTMOThermo Fisher EPS growth masked by currency, says Mizuho
Subscribe for More Information
13:51 EDTPPHMPotential Ebola patient being treated at UC Davis Medical Center, KCRA says
Subscribe for More Information
08:49 EDTTMOThermo Fisher says 'unfavorable' FX masking 'strong' performance
Subscribe for More Information
08:46 EDTTMOThermo Fisher sees 2015 EPS $7.22-$7.40, consensus $7.62
Sees 2015 revenue $16.8B-$17.0B , consensus $17.0B.
06:55 EDTTMOAstraZeneca announces four research collaborations for CRISPR
Subscribe for More Information
06:21 EDTTMOThermo Fisher reports Q4 Life Sciences revenue $1.19B
Subscribe for More Information
06:01 EDTTMOThermo Fisher reports Q4 adjusted EPS $1.99, consensus $1.94
Reports Q4 revenue $4.49B, consensus $4.38B
January 28, 2015
15:38 EDTTMONotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Celgene (CELG), consensus 99c... ConocoPhillips (COP), consensus 59c... Abbott Laboratories (ABT), consensus 67c... Occidental Petroleum (OXY), consensus 68c... Colgate-Palmolive (CL), consensus 74c... Ford (F), consensus 23c... Dow Chemical (DOW), consensus 69c... Alibaba (BABA), consensus 75c... Thermo Fisher (TMO), consensus $1.94; Time Warner Cable (TWC), consensus $2.09... Phillips 66 (PSX), consensus $1.34... Alexion Pharmaceuticals (ALXN), consensus $1.29... Baxter International (BAX), consensus $1.31... Cardinal Health (CAH), consensus $1.10... Raytheon (RTN), consensus $1.08... Northrop Grumman (NOC), consensus $2.25... Viacom (VIAB), consensus $1.28... Valero Energy (VLO), consensus $1.32... Sherwin-Williams (SHW), consensus $1.38... Hershey (HSY), consensus $1.06... Mead Johnson (MJN), consensus 88c... Zimmer (ZMH), consensus $1.71... Xcel Energy (XEL), consensus 34c... Royal Caribbean (RCL), consensus 42c... Coach (COH), consensus 66c... Kate Spade (KATE), consensus 24c... Harley-Davidson (HOG), consensus 34c... Stanley Black & Decker (SWK), consensus $1.52... L-3 Communications (LLL), consensus $2.27... JetBlue (JBLU), consensus 24c.
January 25, 2015
13:57 EDTPPHMUK nurse make full recovery from Ebola, WSJ says
Subscribe for More Information
January 20, 2015
13:09 EDTODPSources: Staples to spurn Starboard's call to merge with Office Depot, FT says
Subscribe for More Information
10:47 EDTODPStaples says will consider 'all actions' that would create shareholder value
Subscribe for More Information
10:23 EDTODPStarboard says Staples should explore merger with Office Depot
Starboard Value, one of the largest shareholders of Staples (SPLS), confirmed, as previously reported, that it has delivered a letter to Ronald Sargent, Chairman and CEO of Staples, and the board of directors of Staples. In the letter, Starboard states in part: "As we discussed in our recent meeting, we believe that the best way to maximize value for Staples' shareholders is through exploring and completing a business combination with Office Depot (ODP). For a variety of reasons, we believe that now is the right time to pursue such a transaction, and we urge you to immediately retain a reputable investment bank and legal advisors to assist the Board in evaluating, structuring and executing a transaction with Office Depot. We believe that a strategic combination of Staples and Office Depot would result in synergies that would more than double the operating profits of the combined company and would create an industry-leading office supply retailer that could more effectively compete against larger retailers and online competitors. The magnitude of value creation from such a business combination far exceeds anything that either company could achieve on a standalone basis. We believe that the evidence is clear that shareholders are broadly supportive of a transaction between Staples and Office Depot. As shown in the chart below, since the merger speculation began last September, Staples' share price has risen over 50%, strongly outperforming the S&P 500...After the recent increase in Staples' share price, we believe the stock now trades at a substantial premium to the intrinsic value of the standalone company. This results in a lower cost of capital for Staples and a stronger currency which could be used to acquire Office Depot. If Staples fails to fully explore and consummate a transaction with Office Depot, shareholders will undoubtedly be extremely disappointed...We understand that this will require cooperation from Office Depot, and we have already expressed to them our strong support for a transaction...Our sincere hope is that we can continue to have a constructive dialogue. However, if it becomes clear to us that you have no intention of seriously pursuing this unique and highly attractive opportunity, it would be a clear sign that significant leadership change is needed at Staples."
09:31 EDTODPActivist Starboard urging Staples, Office Depot to merge, WSJ reports
Subscribe for More Information
08:59 EDTODPStarboard urged Staples to explore Office Depot merger, Bloomberg says
Subscribe for More Information
January 16, 2015
09:31 EDTPPHMPeregrine announces Ohase II clinical data of bavituximab with sorafenib
Peregrine Pharmaceuticals announced the presentation of clinical data related to the company's immuno-oncology development program and its lead investigational immunotherapy drug candidate bavituximab at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. In this single-center, single-arm, open-label investigator-sponsored trial, 38 patients with advanced HCC received bavituximab weekly and sorafenib twice daily until disease progression or toxicity. Data show that the combination of bavituximab and sorafenib is associated with an improved time to progression of 6.7 months, a disease specific survival of 8.7 months, a disease control rate of 58% and a 4-month progression-free survival of 62%. Two patients achieved a partial response according to Response Evaluation Criteria In Solid Tumors. The secondary endpoint of median overall survival was 6.2 months. The combination of bavituximab and sorafenib was well-tolerated in patients with advanced HCC with no indications of autoimmune adverse events that have been seen with other checkpoint immunotherapies.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use